$100M for Talaris Gives Surgeon a Shot to Reinvent Organ Transplants

XCONOMY: When Novartis dissolved its gene and cell therapy unit a few years ago, a bunch of projects the Swiss pharma giant had incubated were tossed aside. One of them was the work of surgeon Suzanne Ildstad, who has spent decades trying to develop a new way to improve the health outcomes of patients who need organ transplants. FULL STORY